A Study in Healthy Female Participants to Investigate the Effect of JNJ-56136379 at Steady-state on the Single-dose Pharmacokinetics of Ethinylestradiol and Drospirenone (Oral Contraceptive) and on the Single-dose Pharmacokinetics of Midazolam (Prob

• Status: Completed
• Trial end date: 2017-08-23

Summary

The main purpose of this study is to evaluate the effect of steady-state concentrations of JNJ-56136379 on the single-dose pharmacokinetics (PK) of drospirenone and ethinylestradiol (oral contraceptive [OC]) in healthy female participants and to evaluate the effect of steady-state concentrations of JNJ-56136379 on the single-dose PK of midazolam (sensitive probe substrate for CYP3A4) in healthy female participants.

• Phase: Phase 1

Details

• Lead Sponsor: Janssen Sciences Ireland UC
• Treatments: Betadex; Contraceptive Agents; Contraceptives, Oral; Drospirenone; Drospirenone and ethinyl estradiol combination; Ethinyl Estradiol; Midazolam